Alopexx (ALPX) sets $10-$12 IPO range after dozens of amendments
Alopexx, Inc. (ALPX), an anti-infective drug developer, has set an IPO price range of $10-$12 per share, with 3 million shares offered. ThinkEquity is leading the underwriting. The small float may lead to significant price volatility post-listing on NYSE American. The final price is pending.
How this was made

The 30-second read
Why it matters
The disclosed price range and share count set expectations for the debut, but the final price will determine the actual market reaction.
Market read
Primary disclosure of IPO terms for a micro‑cap biotech; relevance mainly to IPO‑focused traders.
What to watch
Potential demand from institutional investors and the reputation of ThinkEquity as bookrunner could stabilize the debut.
Background
Alopexx is an anti‑infective drug developer that has filed multiple SEC amendments before finalizing its IPO terms.
Ticker impact
The company announced its IPO price range of $10‑$12 per share for 3 million shares, the first public disclosure of the offering terms.
likely pressure both up and down as the market prices the thin float debut
IPO pricing range is set but final price unknown; thin supply typically amplifies price swings in initial trading.
Market effects
Adds another micro‑cap biotech offering to the biotech IPO pipeline, modest impact on sector supply.
US market sees a new listing on NYSE American; limited broader regional effect.
Low global relevance beyond niche biotech investors.
Counterpoint
Investors may avoid the IPO due to uncertainty over final pricing and potential volatility.
Key entities
- companyAlopexx, Inc.
Anti‑infective drug developer filing for IPO.
- financial_institutionThinkEquity
Bookrunner for the IPO.


